NCT07215949 is a Phase 3 clinical trial of Zilucoplan® in Generalized Myasthenia Gravis (gMG), sponsored by Miriam Freimer.

Who is sponsoring NCT07215949?

NCT07215949 is sponsored by Miriam Freimer.

What drugs are being tested in NCT07215949?

Interventions in NCT07215949: Zilucoplan®.

What condition does NCT07215949 study?

NCT07215949 studies Generalized Myasthenia Gravis (gMG).

Is NCT07215949 still recruiting?

NCT07215949 is currently recruiting now. Last updated 23 February 2026.

Last reviewed 2026-02-23 · How we verify

NCT07215949

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zilucoplan for Severe gMG Exacerbations

Recruiting now Phase 3 Last updated 23 February 2026

What this trial tests

Phase 3 trial testing Zilucoplan® in Generalized Myasthenia Gravis (gMG) in 15 participants. Currently enrolling.

Timeline

20 January 2026

Primary endpoint
1 December 2027

1 April 2028

Quick facts

Lead sponsor	Miriam Freimer
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	20 January 2026
Primary completion	1 December 2027
Estimated completion	1 April 2028
Sites	1 location across United States

Drugs / interventions tested

Zilucoplan®

Conditions studied

Generalized Myasthenia Gravis (gMG) — all drugs for Generalized Myasthenia Gravis (gMG) →

Sponsor

Miriam Freimer

Who can join

18 and older, any sex, with Generalized Myasthenia Gravis (gMG). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks. Participation in the study will last for approximately 18 weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Zilucoplan®

Trials testing the same drug.

NCT04382755 — Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failur · Phase 2 · completed

Other recruiting trials for Generalized Myasthenia Gravis (gMG)

Currently open trials in the same condition.

NCT07247279 — Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia · recruiting
NCT07294170 — ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Particip · recruiting
NCT07284420 — ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With · Phase 2 · recruiting
NCT07058298 — GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103) · EARLY_PHASE1 · recruiting
NCT06312644 — Study of Ultomiris® (Ravulizumab) Safety in Pregnancy · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07215949 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Miriam Freimer
Last refreshed: 23 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07215949.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing